Latest News and Press Releases
Want to stay updated on the latest news?
-
– New publication details the characterization of novel scaffold proteins that can enable engineered exosomes with defined therapeutic properties – – engEx Platform designed to harness exosomes as a...
-
– exoIL-12 resulted in no local or systemic treatment-related adverse events – – Local administration of exoIL-12 demonstrated no systemic exposure to IL-12 – – Dose selection data and advancement...
-
– exoIL-12 has demonstrated tissue-retained pharmacology, enhanced anti-tumor activity, potent M1 myeloid recruitment, and superior T cell responses in vivo – – Novel engineered exosome therapeutic...
-
CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new...
-
– Human clinical testing now underway with Codiak’s first two candidates, exoIL-12™ and exoSTING™ – – Initial safety results and preliminary systemic exposure/pharmacokinetics of exoIL-12 in healthy...
-
– exoIL-12™ demonstrates tissue-retained pharmacology, enhanced anti-tumor activity, potent M1 myeloid recruitment, and superior T cell responses in vivo – – Engineered exosomes with directed...